IDEAYA Biosciences, Inc. (IDYA) stock
IDYANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/307% below fair value
$27.40−2.96 (-9.75%)
Close on Nov 17, 2026Market cap $2.64BP/E –Yield –
IDEAYA Biosciences operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
IDEAYA Biosciences's operating cash flow for the twelve months ending Jun 30, 2026 was -$111.66M. For fiscal 2025 it was -$71.10M. The highest annual figure on record is $55.46M in fiscal 2020.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$71.10M | – |
| FY2024 | Dec 31, 2024 | -$247.58M | – |
| FY2023 | Dec 31, 2023 | -$115.22M | – |
| FY2022 | Dec 31, 2022 | -$87.18M | – |
| FY2021 | Dec 31, 2021 | -$55.78M | -200.6% |
| FY2020 | Dec 31, 2020 | $55.46M | – |
| FY2019 | Dec 31, 2019 | -$39.31M | – |
| FY2018 | Dec 31, 2018 | -$27.62M | – |
| FY2017 | Dec 31, 2017 | -$12.22M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$88.21M | – |
| Q1 FY2026 | Mar 31, 2026 | -$75.17M | – |
| Q4 FY2025 | Dec 31, 2025 | -$90.50M | – |
| Q3 FY2025 | Sep 30, 2025 | $142.21M | – |
| Q2 FY2025 | Jun 30, 2025 | -$62.47M | – |
| Q1 FY2025 | Mar 31, 2025 | -$60.34M | – |
| Q4 FY2024 | Dec 31, 2024 | -$121.66M | – |
| Q3 FY2024 | Sep 30, 2024 | -$49.23M | – |
| Q2 FY2024 | Jun 30, 2024 | -$32.88M | – |
| Q1 FY2024 | Mar 31, 2024 | -$43.81M | – |
| Q4 FY2023 | Dec 31, 2023 | -$23.75M | – |
| Q3 FY2023 | Sep 30, 2023 | -$30.17M | – |
| Q2 FY2023 | Jun 30, 2023 | -$33.46M | – |
| Q1 FY2023 | Mar 31, 2023 | -$27.84M | – |
| Q4 FY2022 | Dec 31, 2022 | -$23.37M | – |
| Q3 FY2022 | Sep 30, 2022 | -$24.17M | – |
| Q2 FY2022 | Jun 30, 2022 | -$19.99M | – |
| Q1 FY2022 | Mar 31, 2022 | -$19.65M | – |
| Q4 FY2021 | Dec 31, 2021 | -$16.66M | – |
| Q3 FY2021 | Sep 30, 2021 | -$12.47M | -113.8% |
| Q2 FY2021 | Jun 30, 2021 | -$12.93M | – |
| Q1 FY2021 | Mar 31, 2021 | -$13.72M | – |
| Q4 FY2020 | Dec 31, 2020 | -$11.60M | – |
| Q3 FY2020 | Sep 30, 2020 | $90.21M | – |
| Q2 FY2020 | Jun 30, 2020 | -$13.61M | – |
| Q1 FY2020 | Mar 31, 2020 | -$9.55M | – |
| Q4 FY2019 | Dec 31, 2019 | -$8.71M | – |
| Q3 FY2019 | Sep 30, 2019 | -$10.55M | – |
| Q2 FY2019 | Jun 30, 2019 | -$10.27M | – |
| Q1 FY2019 | Mar 31, 2019 | -$9.79M | – |
| Q4 FY2018 | Dec 31, 2018 | -$7.48M | – |
| Q3 FY2018 | Sep 30, 2018 | -$8.69M | – |
See a number that looks wrong?